M443

• CAT Number: I020041
• CAS Number: 1820684-31-8
• Molecular Formula: C₃₁H₃₀F₃N₇O₂
• Molecular Weight: 589.61
• Purity: ≥95%
• IUPAC Name: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(1-prop-2-enoylpiperidin-3-yl)pyrimidin-2-yl]amino]benzamide
• InChI: 1S/C31H30F3N7O2/c1-4-28(42)40-11-5-6-22(17-40)26-9-10-35-30(38-26)39-27-12-21(8-7-19(27)2)29(43)37-24-13-23(31(32,33)34)14-25(15-24)41-16-20(3)36-18-41/h4,7-10,12-16,18,22H,1,5-6,11,17H2,2-3H3,(H,37,43)(H,35,38,39)
• InChIKey: QAQFNUYJUCJMKF-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5CCCN(C5)C(=O)C=C

M443 (Cat No.: I020041) is a small-molecule inhibitor studied for its potential role in targeting specific signaling pathways involved in cancer, inflammation, or metabolic diseases. While its precise mechanism of action may vary, M443 is commonly investigated in drug discovery and biomedical research for its effects on cell proliferation, immune modulation, or enzyme inhibition. It serves as a valuable tool in preclinical studies to explore novel therapeutic approaches, particularly in oncology and immunology, where dysregulated signaling contributes to disease progression and treatment resistance.

Reference

[1]. Markowitz D, et al. Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. Mol Cancer Ther. 2016 Aug;15(8):1799-808.